Tag: Cancer: Prostate
USPSTF: Decision to Undergo PSA Screening Should Be Individual
C recommendation for men aged 55 to 69 years; USPSTF recommends against screening for age 70+
Group Exercise, Nutrition Aids Prostate Cancer Patients on ADT
Improvements seen in mobility, body fat, muscle strength in men on androgen-deprivation therapy
Low-Dose Abiraterone Acetate Noninferior for Prostate Cancer
Low-dose AA with low-fat breakfast had greater effect on PSA; similar effect to standard dose
MRI-Targeted Biopsy Noninferior for Prostate Cancer Detection
Clinically significant cancer detected in more men in MRI-targeted biopsy versus standard-biopsy group
Dose-Escalated Radn Does Not Up Survival in Localized Prostate CA
No improvement in overall survival; no difference in cumulative rate of distant metastases
No Benefit for Aggressive Therapy in Metastatic Prostate Cancer
However, mortality higher with conservative therapy in locally advanced, non-metastatic prostate cancer
Single PSA Screening Doesn’t Cut Prostate Cancer Mortality
But screening is associated with increased detection of low-risk prostate cancer
MRI Risk Model May Cut Biopsy Use in Suspected Prostate Cancer
Inclusion of MRI-derived parameters can maintain high rate of diagnosis of clinically significant cancer
FDA Approves Erleada to Treat Non-Metastatic Prostate Cancer
First FDA-approved treatment for non-metastatic, castration-resistant prostate cancer
Criteria for Prostate Cancer Trials Disproportionately Exclude Blacks
Trials sponsored by academic investigators, cooperative groups more likely to use these criteria
